semaglutide glp-1 weight loss clinic Injections for Medical GLP-1 Weight Loss Injections: Semaglutide
Description
On March 20, 2026, Chinas patent on semaglutide (the active ingredient in Ozempic and Wegovy) expiresyears ahead of patent expirations in the U.
Metabolism & Energy: Formulated with ingredients that support metabolic processes and contribute to normal energy-yielding metabolism
My clinical takeaway: Dont discontinue GLP-1s reflexively for fear of NAION
In summary, GLP-1 drugs offer significant advantages for individuals with type 2 diabetes or weight management concerns
